Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live

Donald Trump & Eli Lilly and Company

17 shared events · Importance 7 · Last updated Jun 30, 2026

Importance
7
Shared Events
17
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
59
Domestic
Donald Trump: Donald Trump's comments about a potential end to the Middle East conflict influenced market sentiment, leading to speculation about peace.
Eli Lilly and Company: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
55
Domestic
Donald Trump: Donald Trump announced new tariffs on various imported goods, aiming to boost domestic manufacturing and reduce the budget deficit, despite warnings of increased inflation and harm to consumers.
Eli Lilly and Company: Eli Lilly and Company, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
42
International
Donald Trump: Donald Trump's warnings and threats against Iran contributed to escalating geopolitical tensions and rising oil prices.
Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.
Jun 03, 2026 · 191 articles
24
Domestic
Donald Trump: President Donald Trump has expressed little anxiety about AI displacing human workers, focusing instead on AI-related investments driving economic growth and job availability.
Eli Lilly and Company: Eli Lilly is an employer involved in the RaiseMe project, contributing to the nonprofit's goal of adapting the workforce to an AI economy.
Jun 25, 2026 · 7 articles
0
Business
Aug 14, 2025 · 10 articles
0
Regulatory
Eli Lilly and Company: Eli Lilly and Company agreed to lower prices for its obesity drug Zepbound and will sell a starter dose for $299 a month, with additional doses up to $449, representing $50 reductions from current direct-to-patient prices. Its sales of Zepbound have tripled this year to over $9 billion.
Nov 06, 2025 · 6 articles
0
Domestic
Eli Lilly and Company: Eli Lilly and Company saw gains that helped offset drops in other sectors, contributing to the overall positive market performance.
Dec 11, 2025 · 7 articles
0
Business
Eli Lilly and Company: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
0
Regulatory
Dec 22, 2025 · 23 articles
0
Regulatory
Dec 19, 2025 · 7 articles
0
Business
Feb 24, 2026 · 13 articles
0
Regulatory
Apr 02, 2026 · 23 articles
0
International
Apr 01, 2026 · 23 articles
0
International
Apr 01, 2026 · 16 articles
0
Domestic
Apr 02, 2026 · 6 articles
0
Business
Apr 01, 2026 · 7 articles
0
International
Apr 01, 2026 · 15 articles
NEWSDESK
Explore this relationship live

Track how Donald Trump and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.